S-1: Oaktree Acquisition Corp. III Life Sciences Files for $175 Million IPO Targeting Healthcare Sector

Oaktree Acquisition Corp. III Life Sciences, a blank check company affiliated with Oaktree Capital, aims to raise $175 million in an IPO to pursue a business combination within the healthcare industry.

Summary

• Oaktree Acquisition Corp. III Life Sciences has filed an S-1 registration statement for a $175 million IPO.
• The company is a newly organized blank check company focusing on the healthcare and healthcare-related industries.
• The IPO will offer 17,500,000 units at $10.00 per unit, each consisting of one Class A ordinary share and one-fifth of one redeemable warrant.
• The company intends to target North American, British, or European companies in biopharmaceuticals, medical devices, diagnostics, and specialized healthcare services.
• Oaktree Acquisition Corp. III Life Sciences is affiliated with Oaktree Capital Management, which has approximately $193 billion in assets under management as of June 30, 2024.
• The underwriters have a 45-day option to purchase up to 2,625,000 additional units to cover over-allotments.
• Approximately $175 million from the offering will be deposited into a trust account.
• The company must complete a business combination with a fair market value of at least 80% of the net assets held in the trust account.
• If a business combination is not completed within 24 months, the company will redeem 100% of the public shares for cash.
• The sponsor, Oaktree Acquisition Holdings III LS, LLC, will purchase 550,000 private placement units at $10.00 per unit, totaling $5.5 million.

Sentiment

Score: 6

Explanation: The document is neutral in tone, presenting factual information about the IPO and the company's plans. While it highlights positive aspects like the management team's experience and the growth potential of the healthcare sector, it also acknowledges the risks and challenges associated with blank check companies.

Positives

• The company is affiliated with Oaktree Capital Management, a well-established investment firm.
• The management team has experience with previous SPAC transactions, including Hims & Hers Health, Inc. and Alvotech.
• The healthcare sector is experiencing continuous innovation and rapid technological advancements.
• Oaktree's Life Sciences team has committed approximately $5 billion across 51 life sciences investments since 2013 with no realized losses.

Negatives

• The company is a blank check company with no operating history or revenues.
• The company has a limited time (24 months) to complete a business combination.
• The company may face competition from other SPACs seeking target businesses.
• The company's success depends on the management team's ability to identify and acquire a suitable target.
• The company may be affected by numerous risks inherent in a target business that is financially unstable or in its early stages of development or growth.

Risks

• The company may not be able to identify a suitable target business or complete a business combination within the required timeframe.
• The company may face increased competition for attractive target businesses, potentially increasing the cost of a business combination.
• The company's management team may have conflicts of interest in allocating their time and resources.
• The company may be affected by numerous risks inherent in a target business that is financially unstable or in its early stages of development or growth.
• The company may be unable to obtain additional financing to complete a business combination or fund the operations and growth of a target business.
• The company may be deemed an investment company under the Investment Company Act of 1940, which could result in burdensome compliance requirements and restrictions on its activities.
• The company may be a passive foreign investment company, which could result in adverse U.S. federal income tax consequences to U.S. investors.

Future Outlook

The company intends to focus on opportunities in the healthcare or healthcare-related industries in North America, the United Kingdom, and Western Europe, and to capitalize on the ability of its management team to identify and acquire a business.

Industry Context

The healthcare sector has seen continuous innovation and rapid technological advancements over the last decade, making it one of the fastest-growing industries, driven by ongoing research into new treatment areas and disease states as well as by favourable demographic tailwinds given rapidly aging populations in developed markets.

Comparison to Industry Standards

• Oaktree has a track record in the healthcare SPAC space with previous de-SPACing acquisitions of Hims & Hers Health, Inc. (NYSE: HIMS) and Alvotech (NASDAQ: ALVO).
• Oaktree's SPACs have generated an equity return of approximately 40% since 2020.
• The life sciences sector is the most active with 168 transactions raising $34 billion in proceeds year-to-date.
• The life sciences sector has a large backlog of companies with only 11 IPOs completed year-to-date and 23,000 life sciences companies globally.

Related Party Transactions

• The sponsor will purchase $5.5 million in private placement units.
• The company will pay the sponsor $25,000 per month for office space, secretarial, and administrative services.
• The company may repay loans from the sponsor, affiliates, or officers and directors to finance transaction costs.
• The company will indemnify the sponsor and its affiliates from certain liabilities.

Stakeholder Impact

• Shareholders will have the opportunity to redeem their shares upon completion of a business combination.
• Shareholders may experience dilution from the issuance of additional shares or the conversion of founder shares.
• The company's success depends on the management team's ability to identify and acquire a suitable target business.
• Employees of a target business may be affected by changes in management or operations following a business combination.

Next Steps

• The company will communicate with its management's network of deal sourcing relationships to articulate the parameters for its search for a potential business combination.
• The company will conduct a thorough due diligence review of prospective target businesses.
• The company will negotiate and structure the terms of a business combination transaction.

Key Dates

Keywords

SPAC, healthcare, business combination, Oaktree, IPO, acquisition, blank check company, life sciences, investment, merger